Farm animals will have nothing to do with him. Furthermore, he'll have to resort to using his left hand because his right hand has already rejected him. He's really running out of options.
I was just reading through some posts and learned that if (bad) news comes out, the stock could go to zero. This is very insightful and shocking news. Wait a minute. No, it's not.
No $#it Sherlock. Everyone knows and understands the notion that bad news will make this stock essentially worthless. Heck, its almot worthless now. What we don't know is what the pps will be IF good news comes out. Note: I said "IF" not when.
Sorry dude but the last sentence in your post just rubbed me the wrong way.
"Without that, investors are just guessing."
Investing is all about guessing. First you do your DD. Then you make your best guess and place your bet. Sometimes you guess wrong, sometimes you guess right, and sometimes you get lucky (bad lucky or good lucky).
"Would it Kill you to give us an update..."
Savvy - I hear ya man. I sent an email to Takeda last week seeking an update. Unfortunately, I began my email with "As an Affymax investor..." That, of course, made it too easy. Takeda did not answer any of my questions but encouraged me to contact Affymax directly by providing me with the phone number and email address of a contact from the Brenner group.
So, I sent TBG an email and he responded. He confirmed that the Omontys investigation is still ongoing with Takeda. I also asked him about the timeline and next steps but he has no visibility into this since Takeda is working directly with the FDA on this matter.
What management? There is no management.
This thing isn't going to move up or down in any sigificant way until real news hits.
Schwab removed the previously posted low ($0.425) for the day and replaced it with $0.81. ...like it never even happened. Yet. They forgot to adjust the chart which still shows the day stating out in sub $0.50 territory. Senator, I have no recollection of those events.
So many sleazy games on Wall Steet.
"Yeah, if it really happened. Some novice or someone made a careless mistake, or it was a misprint. Hard to see how it could happen if there were bids in at the higher levels."
As George Carlin said "it's a big club and you ain't in it." In my opinion this was a signal to the club members that the end is near so either get out or get in. I have no idea what it means other than I'm sure there is corruption behind it. I've seen it before on both ends of the spectrum where there was a few shares traded at a 50% discount or a 50% premium for no apparent reason. It's all BS and the game is rigged.
Yes. I saw it.
Schwab shows the day low as 0.425. The corruption in the markets is unbelievable. I've seen this same type of BS in others stocks where a 50% or greater discount is made a available to a few select people with crooked connections.
Hello analinspection. So, how far up your #$%$ does your head need to be in order to perform a proper analinspection. Judging from your post... pretty far up there.
jpc270 - If you sold a month ago, why are you posting today? Iggy...
Meant to say... I looked on both Takeda and Takeda USA's website and there is NO recent press release on either site related to this topic.
I was looking for independent confirmation and found the January press release. Also, I looked on both Takeda and Takeda USA's website and there is I recent press release related to this topic.
Just because it was posted on yahoo... does not make it true. Of course, this applys equally to all pumper and basher posts.
That news is from January, 2013. ???
Affymax and Takeda Announce Permanent J-Code for OMONTYS® (peginesatide) Injection is in Effect
Code J0890 Effective As of January 1, 2013
PALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for OMONTYS® (peginesatide) Injection is now effective. This permanent OMONTYS-specific billing code, J0890, will continue to provide for streamlined reimbursement for dialysis organizations prescribing OMONTYS. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the adult dialysis patient population with chronic kidney disease (CKD) in the United States (U.S.).
"We are excited by the strong level of interest in the dialysis community for OMONTYS," said John Orwin, chief executive officer, Affymax. "We believe the J-code complements our efforts to make this once-monthly therapy broadly available to the dialysis community, and importantly, to appropriate patients."
According to Nicole Mowad-Nassar, vice president, marketing at Takeda, "We are pleased to have an effective J-code in place approximately nine months following the approval of OMONTYS."
OMONTYS was approved by the U.S. Food and Drug Administration (FDA) on March 27, 2012, for the treatment of anemia due to CKD in adult patients on dialysis. OMONTYS is not indicated and is not recommended for use in patients with CKD not on dialysis, in patients receiving treatment for cancer and whose anemia is not due to CKD, or as a substitute for red blood cell (RBC) transfusions in patients who require immediate correction of anemia. OMONTYS has not been shown to improve symptoms, physical functioning, or health-related quality of life. Please see Important Safety Information including Boxed WARNINGS below.
Information on OMONTYS Reimbursement Support
Customers seeking additional information about accessing the product can refer to the OMONTYS Reimbursement Access Support (RAS) program. RAS offers comprehensive reimbursement access, and support services for healthcare providers. For more information please call 1-855-GOMONTYS (1-855-466-6689) for more information.
I had my Buy order in at 1.23 but the MMs only gave me 100 shares. I may lower my ask tomorrow. Just trying to get a few more cheap shares. :)